In the long work of keeping people alive, cardiovascular disease has remained the foremost killer, even as the science of preventing it has grown sharper and more certain. The American College of Cardiology has now set out ADVANCE-ASCVD, an effort to narrow the stubborn gap between what research has proven and what clinics actually deliver to patients. Its aim is not only to treat hearts after they falter, but to find risk early, across whole populations, before the damage begins.
ACC Launches ADVANCE-ASCVD to Close Gaps in Cardiovascular Disease Prevention
Treat disease better after it occurs, or identify risk before it develops
Mark
So what is ADVANCE-ASCVD, in plain terms?
Mimi
It's an American College of Cardiology initiative to reduce heart attacks, strokes and related events across populations by closing the gap between prevention evidence and what happens in clinics.
Mark
Why is there a gap if we already know lowering LDL works?
Mimi
Because many high-risk patients are still above their LDL-C targets. The announcement says guideline-directed care is applied inconsistently in real-world practice.
Luke
Worth saying that's the ACC's own characterization. The announcement gives no figures for how many patients miss targets.
Mark
Mehran talks about moving from snapshots to continuous assessment. What does that mean?
Mimi
Instead of checking risk at occasional visits, tracking it over time so intervention can come before disease develops. That's her framing of where prevention is heading.
Luke
It's a description of direction, not a demonstrated result. Nothing here says how continuous assessment will be done.
Mark
The fifth pillar mentions AI. Is that central?
Mimi
It's one part of the innovation pillar, alongside digital health and the ACC's global network, meant to develop and scale new prevention strategies.
Luke
And no specific tools or trials are named. We don't know yet what that will look like.
Mark
So what would success look like?
Mimi
More high-risk patients reaching LDL-C targets, but the announcement sets no timelines or numeric goals, so that remains to be seen.
El Pulso
- Cardiovascular disease still leads global causes of death, even though therapies that lower LDL cholesterol are well proven.
- Many high-risk patients remain above their LDL targets, exposing a widening distance between evidence and everyday care.
- The American College of Cardiology has launched ADVANCE-ASCVD, built on five pillars spanning education, implementation, evidence, patient engagement and innovation.
- Artificial intelligence and digital health are being pressed into service to catch risk earlier, but no results or timelines have been published yet.
In the long work of keeping people alive, cardiovascular disease has remained the foremost killer, even as the science of preventing it has grown sharper and more certain. The American College of Cardiology has now set out ADVANCE-ASCVD, an effort to narrow the stubborn gap between what research has proven and what clinics actually deliver to patients. Its aim is not only to treat hearts after they falter, but to find risk early, across whole populations, before the damage begins.
The American College of Cardiology has announced ADVANCE-ASCVD, a new initiative aimed at reducing atherosclerotic cardiovascular disease events across entire populations. Its target is a familiar and frustrating problem: the gap between what prevention research has shown works and what actually happens in clinics and hospitals.
ASCVD remains the leading cause of death worldwide, despite decades of progress. The evidence that lowering LDL cholesterol reduces heart attacks, strokes and cardiovascular deaths is firm, yet many high-risk patients still sit above their targets. Turning that evidence into consistent care in daily practice has proven uneven.
The ACC frames the opportunity as a shift from treating disease after it appears to finding risk sooner. ACC President Roxana Mehran described prevention moving from occasional snapshots toward continuous, longitudinal assessment.
The initiative rests on five pillars: education and practical resources for clinicians, implementation science and decision support, real-world evidence and pragmatic research, patient awareness and earlier risk identification, and innovation using digital health and AI across regions. The announcement outlines goals rather than results, with no timelines or numeric targets. The real test is whether these efforts move more high-risk patients to their LDL-C goals in actual practice.
The American College of Cardiology has announced a new initiative called ADVANCE-ASCVD, aimed at cutting the number of atherosclerotic cardiovascular disease events across whole populations. The target is a specific and stubborn problem: the distance between what research has shown works for prevention and what actually happens in clinics and hospitals.
The starting point is a familiar one. ASCVD is the leading cause of death worldwide, even after decades of progress in both treatment and prevention. The evidence that lowering low-density lipoprotein cholesterol, the so-called bad cholesterol, significantly reduces the risk of heart attack, stroke and cardiovascular death is well established. Yet many patients at high risk for ASCVD remain above their LDL-C targets. According to the announcement, turning the evidence into consistent, guideline-directed care in everyday practice is uneven.
The ACC describes ADVANCE-ASCVD as an effort to translate evidence into practice and to improve how cardiovascular risk is identified and managed across diverse populations and care settings. Its framing is that the opportunity is no longer only to treat disease better after it appears, but to find risk earlier and intervene before disease develops.
Roxana Mehran, MD, FACC, the ACC's president, put it in those terms. She said prevention is moving from periodic snapshots toward continuous, longitudinal assessment, and that ADVANCE-ASCVD pushes forward what she called one of the most important shifts in cardiovascular care since preventive therapies became widely adopted.
The initiative is organized around five strategic pillars. The first, education and knowledge dissemination, will develop guideline-aligned education and practical resources to help clinicians, care teams and health systems apply evolving prevention evidence. The second, clinical implementation and decision science, will use implementation science, quality improvement and decision-support strategies to tackle the barriers that slow adoption of evidence and to improve systems of care.
The third pillar, evidence and insight generation, relies on real-world data, clinician insights and pragmatic research to understand patterns of care, identify gaps and evaluate ways to improve prevention. The fourth, patient and population health, focuses on raising patient awareness, engagement and activation, while advancing scalable ways to identify risk earlier across diverse populations.
The fifth pillar, innovation and global scale, draws on digital health, artificial intelligence and other emerging technologies, along with the ACC's global network, to develop, test and expand new prevention strategies across different care settings and regions.
The announcement describes goals and structure rather than results, and it offers no timelines or numeric targets. What to watch is whether the pillars, particularly the push toward earlier risk identification and the use of digital tools, begin to move more high-risk patients to their LDL-C targets in real-world practice.
Citas Notables
Prevention is moving from periodic snapshots to continuous, longitudinal assessment, and ADVANCE-ASCVD propels one of the most important shifts in cardiovascular care since preventive therapies were widely adopted.— Roxana Mehran, MD, FACC, ACC President (paraphrased)
Quieres la nota completa?
Lee el original en News-Medical ↗